Positron achieves highest possible compliance notice from Nuclear Regulatory Commission

Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, today announced it had achieved the highest mark of compliance in a recent inspection by the Nuclear Regulatory Commission (NRC).

“Our internal processes and controls are always driven to ensure we adhere to the highest degree of compliance, this is further evidence of Positron's overall commitment to excellence”

The NRC performed a safety inspection of Positron's Indianapolis facility this past Thursday and issued a compliance report (FORM 591M Part 1) with its findings. The report indicated Positron achieved the highest possible compliance notice (with no violations) available from this Federal regulatory body, which monitors radioactive material (RAM) license holders.

"The NRC has a strong reputation for rigorousness and insistence on its standards of procedural verification, training and documentation. A RAM license is key to our radiopharmaceutical programs in order to conduct critical research & development and manufacturing, now and in the future. More immediately, we will be conducting validation testing prior to shipment of commercial products from our Nuclear Cardio-Assist™ line."

"Our internal processes and controls are always driven to ensure we adhere to the highest degree of compliance, this is further evidence of Positron's overall commitment to excellence," stated Positron CEO Patrick G. Rooney.

The NRC periodically inspects the procedures and documentation of RAM license holders, such as imaging centers, nuclear pharmacies and producers of radioactive products, to ensure safe and proper handling of radioactive material. Inspections are an examination of the activities conducted under a license issued by the NRC, an independent Federal agency. A RAM license is required to produce and handle radioactive pharmaceuticals. Positron received its RAM license from the NRC in December 2009 to support its imaging device and pharmaceutical programs.